Literature DB >> 24732333

Dormant melanomas or changing nevi?

Giuseppe Argenziano1, Aimilios Lallas2, Caterina Longo2, Elvira Moscarella2, Margherita Raucci2, Iris Zalaudek3.   

Abstract

The development of new primary melanomas in patients treated with vemurafenib has been reported recently in a study by Perier-Muzet et al. The primary outcome of the study was to describe the dermoscopic changes that prompted excision of those melanomas. However, the crucial point raised by the study is the large number of melanomas that were detected.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24732333     DOI： 10.1038/jid.2013.512

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN： 0022-202X            Impact factor:   8.551


  9 in total

1.  Pseudomelanoma: recurrent melanocytic nevus following partial surgical removal.

Authors:  R Kornberg; A B Ackerman
Journal:  Arch Dermatol       Date:  1975-12

2.  Vemurafenib in melanoma with BRAF V600E mutation.

Authors:  Stéphane Dalle; Nicolas Poulalhon; Luc Thomas
Journal:  N Engl J Med       Date:  2011-10-13       Impact factor: 91.245

3.  The dermoscopical and histopathological patterns of nevi correlate with the frequency of BRAF mutations.

Authors:  Iris Zalaudek; Christian Guelly; Giovanni Pellacani; Rainer Hofmann-Wellenhof; Slave Trajanoski; Harald Kittler; Alon Scope; Ashfaq A Marghoob; Caterina Longo; Bernd Leinweber; Gerardo Ferrara; Toshiaki Saida; James M Grichnik; Giuseppe Argenziano; Jürgen C Becker
Journal:  J Invest Dermatol       Date:  2010-11-11       Impact factor: 8.551

4.  Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition.

Authors:  Lisa Zimmer; Uwe Hillen; Elisabeth Livingstone; Mario E Lacouture; Klaus Busam; Richard D Carvajal; Friederike Egberts; Axel Hauschild; Mohammed Kashani-Sabet; Simone M Goldinger; Reinhard Dummer; Georgina V Long; Grant McArthur; André Scherag; Antje Sucker; Dirk Schadendorf
Journal:  J Clin Oncol       Date:  2012-05-21       Impact factor: 44.544

5.  UV-irradiated melanocytic nevi simulating melanoma in situ.

Authors:  M Tronnier; H H Wolff
Journal:  Am J Dermatopathol       Date:  1995-02       Impact factor: 1.533

6.  Dynamic changes in nevi of a patient with melanoma treated with vemurafenib: importance of sequential dermoscopy.

Authors:  Holger A Haenssle; Sophie L Kraus; Franziska Brehmer; Lutz Kretschmer; Bernward Völker; Hiba Asper; Alexander Kapp; Ralf Gutzmer
Journal:  Arch Dermatol       Date:  2012-10

7.  Multiple primary melanoma.

Authors:  H S Moseley; A E Giuliano; F K Storm; W H Clark; D S Robinson; D L Morton
Journal:  Cancer       Date:  1979-03       Impact factor: 6.860

8.  Melanoma patients under vemurafenib: prospective follow-up of melanocytic lesions by digital dermoscopy.

Authors:  Marie Perier-Muzet; Luc Thomas; Nicolas Poulalhon; Sébastien Debarbieux; Pierre-Paul Bringuier; Gerard Duru; Lauriane Depaepe; Brigitte Balme; Stephane Dalle
Journal:  J Invest Dermatol       Date:  2013-11-07       Impact factor: 8.551

9.  Meta-analysis of digital dermoscopy follow-up of melanocytic skin lesions: a study on behalf of the International Dermoscopy Society.

Authors:  G Salerni; T Terán; S Puig; J Malvehy; I Zalaudek; G Argenziano; H Kittler
Journal:  J Eur Acad Dermatol Venereol       Date:  2012-11-26       Impact factor: 6.166
  9 in total
  2 in total

Review 1.  Management of the cutaneous adverse effects of antimelanoma therapy.

Authors:  Rose Congwei Liu; Germana Consuegra; Pablo Fernández-Peñas
Journal:  Melanoma Manag       Date:  2017-11-22

Review 2.  Treating advanced melanoma: current insights and opportunities.

Authors:  Michael Tronnier; Christina Mitteldorf
Journal:  Cancer Manag Res       Date:  2014-09-10       Impact factor: 3.989
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.